Floatz logo

Cyclophosphamide

Sleep Disturbance

University of WashingtonSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Sleep Disturbance cohort.

Asset / SponsorPhaseRating
Solriamfetol
Duke University
Phase 2B
MIDAZOLAM
Sixth Affiliated Hospital, Sun Yat-sen University
N/AD
Inno-206
University of Washington
N/AD

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →